Lupin, a global pharmaceutical company based in Mumbai, India, has launched Dapagliflozin and Metformin Hydrochloride extended-release tablets in the United States following approval from the U.S. Food and Drug Administration (FDA). This medication, available in strengths of 5 mg/500 mg, 5 mg/1,000 mg, 10 mg/500 mg, and 10 mg/1,000 mg, is designed to enhance glycemic control in adults with type 2 diabetes and is bioequivalent to Xigduo XR. In financial results for the third quarter of FY26, Lupin reported a 37.46% increase in consolidated net profit, reaching ₹1,175.55 crore (approximately $142 million USD) compared to ₹855.16 crore (approximately $103 million USD) in the same period last year. Additionally, total revenue from operations surged 24.26% year-on-year to ₹7,167.52 crore (approximately $865 million USD). Despite these positive results, Lupin's stock price decreased by 0.10%, closing at ₹2,309.45 (approximately $28 USD) on the Bombay Stock Exchange (BSE).